The state and consequences of dermatology drug prices in the United States
Division of Dermatology, Department of Medicine
Dermatology | Pharmacoeconomics and Pharmaceutical Economics
In 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.
coinsurances, drug pricing, formulary tiering, generic drugs, out-of-pocket costs, pharmacy benefit managers, prior authorizations
Rights and Permissions
Citation: J Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. Link to article on publisher's site
Journal of the American Academy of Dermatology
Albrecht, Joerg; Maloney, Mary E.; and Brod, Bruce Alan, "The state and consequences of dermatology drug prices in the United States" (2016). University of Massachusetts Medical School Faculty Publications. 1301.